
This information was provided by prnewswire
Send your Press Release here.
Dr. Small-Howard explains the mechanisms for the treatment of chronic and neuropathic pain using proprietary, cannabis-based formulations
LAS VEGAS, Oct. 9, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) announces that their Chief Science Officer, Dr. Andrea Small-Howard , will be presenting the results of GB Sciences’ novel pain formulation research project during the poster session for CannMed 2018 to be held at the UCLA Luskin Conference Center from October 22nd to October 24th.
According to the conference organizers, “CannMed 2018 is a gathering of the greatest minds in medical cannabis, where they will further the convergence of medical cannabis research, treatment, and product development. The world’s top medical cannabis researchers will present their latest findings with regards to the efficacy of treating a variety of conditions with cannabis. Clinicians will share compelling case studies and clinical pearls they have collected through their experience treating patients with cannabis. Cannabis industry leaders will also share how they are adopting innovative testing methods and technologies to create new products that move the industry forward.”
“CannMed 2018 is the perfect venue for sharing the scientific research supporting our proprietary, cannabis-based formulations for the treatment of chronic and neuropathic pain because of the superb academic and clinical credentials of the presenters and attendees at CannMed,” said Dr. Small-Howard. “GB Sciences will further be presenting information on its medical cannabis product lines in booth 202. These products are designed to be sold in Nevada and Louisiana. We hope that interested participants will visit us!”
John Poss, CEO and Chairman of GB Sciences said “We are proud to be a part of CannMed 2018. In gathering all these impressive scientists, researchers and inventors, we celebrate the future of healing. This is the inspiration for GB Sciences.”
Leave a Reply